Cargando…
Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016
BACKGROUND: Direct-acting anti-viral agents have improved the treatment of chronic hepatitis C virus (HCV) infection, but this treatment is challenging for patients using co-medications because of potential drug–drug interactions. This study aimed to examine the comorbidities and co-medications of J...
Autores principales: | Ruzicka, Daniel J., Tetsuka, Jumpei, Fujimoto, Go, Kanto, Tatsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968711/ https://www.ncbi.nlm.nih.gov/pubmed/29793436 http://dx.doi.org/10.1186/s12879-018-3148-z |
Ejemplares similares
-
Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study
por: Tanaka, Junko, et al.
Publicado: (2022) -
Hepatitis Action Plan and Changing Trend of Liver Disease in Japan: Viral Hepatitis and Nonalcoholic Fatty Liver Disease
por: Kanto, Tatsuya, et al.
Publicado: (2017) -
Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study
por: Masaki, Naohiko, et al.
Publicado: (2015) -
Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan
por: Ashraf Hussain, Md Razeen, et al.
Publicado: (2022) -
Calibrating Hepatitis E Virus Serological Assays Using Asymptomatic Specimens Obtained in Japan
por: Terahara, Kazutaka, et al.
Publicado: (2022)